Browse MFAP2

Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF05507 Microfibril-associated glycoprotein (MAGP)
PF01549 ShK domain-like
Function

Component of the elastin-associated microfibrils.

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0007423 sensory organ development
GO:0009791 post-embryonic development
GO:0009886 post-embryonic animal morphogenesis
GO:0030198 extracellular matrix organization
GO:0043062 extracellular structure organization
GO:0048048 embryonic eye morphogenesis
GO:0048050 post-embryonic eye morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048563 post-embryonic animal organ morphogenesis
GO:0048568 embryonic organ development
GO:0048569 post-embryonic animal organ development
GO:0048592 eye morphogenesis
GO:0090596 sensory organ morphogenesis
Molecular Function -
Cellular Component GO:0001527 microfibril
GO:0005578 proteinaceous extracellular matrix
GO:0043205 fibril
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-2129379: Molecules associated with elastic fibres
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MFAP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MFAP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MFAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-3.0590.000102
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-4.0870.103
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-2.2980.204
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3350.567
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0970.946
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6160.786
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3220.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.1730.399
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4830.773
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0070.996
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5350.41
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.010.96
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MFAP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MFAP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MFAP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MFAP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MFAP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MFAP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MFAP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMFAP2
Namemicrofibrillar-associated protein 2
Aliases MAGP; MAGP-1; MAGP1; microfibril-associated glycoprotein 1; MFAP-2
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MFAP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.